Axsome Therapeutics, Inc.
AXSM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001579428
In the last 90 days, Axsome Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 508 institutions reported holding it in 13F filings for Q2 2026, worth $9.34B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 9, 2026
- $7.05B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $2.09M in total
- 1
- 13F holdersQ2 2026, +96 vs. previous quarter
- 508
- 13F valueReported value at the end of Q2 2026
- $9.34B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $638.5M
- +65.5% year over year
- Net income, FY2025
- -$183.2M
- No comparable prior period
- Free cash flow, FY2025
- -$93.9M
- No comparable prior period
- Revenue, Q3 FY2026
- $259.7M
- +51.9% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $183.2M (28.7% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 3.11M
- Shares sold short
- Change
- −194.8K
- −5.9% vs. previous
- Days to cover
- 3.34
- At average daily volume
Superinvestors holding AXSM, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding AXSM at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Axsome Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 (view filing)7:09 PM ET | Sep 3 | Same day | Jacobson Mark L.Chief Operating Officer | SSale | −10.0K | $208.65 | −$2.09M | −100.0%0 after | 10b5-1 |
| Aug 7, 2026 (view filing)7:00 PM ET | Aug 5-6 | 2 days | Tabuteau HerriotChief Executive Officer | SSale | −49.7K | $212.19 | −$10.5M | −87.3%7.23K after | 2 lots10b5-1 |
| Jul 1, 2026 (view filing)7:30 PM ET | Jul 1 | Same day | Tabuteau HerriotChief Executive Officer | SSale | −49.7K | $240.25 | −$11.9M | −87.3%7.23K after | 10b5-1 |
| Jun 11, 2026 (view filing) | Jun 10-11 | 1 day | Jeffs RogerDirector | SSale | −572 | $247.65 | −$141.7K | −1.0%58.4K after | 2 lots10b5-1 |
| Jun 10, 2026 (view filing) | Jun 9-10 | 1 day | Mahony SusanDirector | SSale | −600 | $241.70 | −$145.0K | −42.0%829 after | 2 lots10b5-1 |
| Jun 10, 2026 (view filing) | Jun 10 | Same day | Coleman MarkDirector | SSale | −643 | $249.00 | −$160.1K | −2.1%30.4K after | 10b5-1 |
| Jun 9, 2026 (view filing) | Jun 9 | Same day | Tabuteau HerriotChief Executive Officer | SSale | −49.7K | $241.01 | −$12.0M | −87.3%7.23K after | 10b5-1 |
| Jun 9, 2026 (view filing) | Jun 9 | Same day | Pizzie NickChief Financial Officer | SSale | −33.0K | $240.09 | −$7.92M | −43.5%42.9K after | 10b5-1 |
| Jun 2, 2026 (view filing) | May 29-Jun 2 | 4 days | Coleman MarkDirector | SSale | −17.5K | $229.20 | −$4.02M | −37.2%29.6K after | 3 lots10b5-1 |
| May 5, 2026 (view filing) | May 4-5 | 1 day | Jacobson Mark L.Chief Operating Officer | SSale | −4.75K | $227.95 | −$1.08M | −100.0%0 after | 2 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 508 holdersThe largest institutional positions in Axsome Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 3,103,708 | $759.7M | 0.01% | −809,136−20.7% | Reduced |
| Vanguard Portfolio Management LLC | 1,983,514 | $485.5M | 0.02% | −74,656−3.6% | Reduced |
| Vanguard Capital Management LLC | 1,965,086 | $481.0M | 0.01% | +27,334+1.4% | Added |
| Invesco Ltd. | 1,671,684 | $409.2M | 0.03% | +374,006+28.8% | Added |
| FMR LLC | 1,539,163 | $376.7M | 0.02% | −27,832−1.8% | Reduced |
| Geode Capital Management, LLC | 967,172 | $236.8M | 0.01% | −195,809−16.8% | Reduced |
| Morgan Stanley | 804,082 | $196.8M | 0.01% | +327,381+68.7% | Added |
| State Street Corp | 785,661 | $192.3M | 0.01% | −201,148−20.4% | Reduced |
| Deep Track Capital, LP | 700,000 | $171.3M | 2.52% | −400,000−36.4% | Reduced |
| Two Sigma Investments, LP | 669,478 | $163.9M | 0.12% | +346,700+107.4% | Added |
Holders of 5% or more of AXSM
See all 1 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Axsome Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 5.30%2.74M shares | – | Jul 27, 20261 filing | Jul 27, 2026 | SEC |
Politician trades
All politician trades in AXSM1 member of Congress reported 1 trade in Axsome Therapeutics, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Jul 28, 2022 |  Chris Jacobs House · NY | Buy | $15K-$50K |
House · NY · Jul 28, 2022
Buy$15K-$50K